首页工具

登录

搜索结果

Search Results for " screening "

Targets Recommended: Others

44

抑制剂 & 化合物

12

天然产物

144

化合物库

40

重组蛋白

2

同位素标记化合物

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name
L9500	表型筛选靶点鉴定库		1796 compounds
	1796 种靶点明确的已知活性化合物，适合表型筛选；
L6001	Mini真菌代谢天然产物筛选库		Inquiry

LF9000	半胱氨酸靶向共价抑制剂库		3400 compounds
	It contains over 3,400 potential covalent modifiers.
L5600	Mini骨架库		5000 compounds
	多样性好，从一百多万个小分子中挑选而出，5000 个化合物代表5000 种骨架结构；
L5610	Golden骨架库		10000 compounds
	多样性好，从160万个小分子中挑选而出，10000 个化合物，5000种骨架结构；
L6900	稀有天然产物库		693 compounds
	693 种稀有天然产物的集合，可以用于高通量和高内涵筛选；
L4500	抗真菌库		252 compounds
	252 个抗真菌活性化合物的独特集合，包含作用于真菌相关靶点的化合物和临床中用于真菌类疾病的药物，是相关疾病药物筛选的有效工具。
L6100	天然多酚类化合物库		635 compounds
	635 个天然多酚化合物的独特集合，可用于高通量、高内涵筛选；
L2700	肾上腺素能受体化合物库		193 compounds
	193 种特异靶向肾上腺素受体的生物活性小分子化合物的集合，是相关疾病药物筛选的有效工具；
L3410	临床前化合物库		701 compounds
	701 种临床前小分子化合物的特有集合，用于高通量、高内涵筛选；
L3900	DNA 损伤和修复分子库		910 compounds
	910 个与 DNA 损伤和修复紧密相关的化合物集合，是高通量筛选，高内涵筛选的良好载体；
L2000	抑制剂库		8328 compounds
	8328 个小分子抑制剂的独特集合，主要用于细胞信号研究、新药筛选、高通量筛选和高内涵筛选；
L9100	磷酸酶抑制剂化合物库		79 compounds
	79 种已知活性的磷酸酶抑制剂的集合，可用于化合物筛选、化学基因组学、药理分析等方面；
L2400	内分泌激素分子库		784 compounds
	784 种与内分泌系统相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L4200	FDA 上市药物库		1729 compounds
	1729 个FDA 批准药物的独特集合，可用于高通量筛选和高内涵筛选；
L5200	抗代谢疾病化合物库		1544 compounds
	1544 个代谢疾病相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L1200	表观遗传库		953 compounds
	953 种表观遗传学研究相关的生物活性小分子的特有集合，用于表观遗传学研究及其相关的检测和高通量、高内涵筛选；
L8000	干细胞分化化合物库		1197 compounds
	1197 种干细胞分化信号通路相关的生物活性小分子化合物的特有集合，可用于高通量、高内涵筛选；
L9240	农药化合物库		270 compounds
	270种农药相关化合物的独特集合，可用于高通量筛选和高内涵筛选；
L2120	抗癌临床化合物库		2545 compounds
	2545 个具有抗癌活性小分子的独特集合，可用于高通量高内涵筛选。
L7000	活性脂质化合物库		385 compounds
	385 种生物活性小分子化合物，用于高通量、高内涵筛选；
L3400	临床期小分子药物库		3404 compounds
	3404 个临床期化合物集合，可用于高通量筛选和高内涵筛选；
L6030	天然产物衍生物虚筛化合物库		163000 compounds
	16.3万种天然产物衍生物，并且在持续增加中；
L2800	5-羟色胺分子库		268 compounds
	268 种生物活性小分子化合物，用于高通量、高内涵筛选；
L1710	抗COVID-19化合物库		1133 compounds
	1133 种对SARS-CoV-2有抑制作用或潜在抑制作用的化合物集合，可用于高通量和高内涵筛选；
L8100	细胞周期化合物库		677 compounds
	677 种细胞周期相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L6600	胃肠炎天然产物库		219 compounds
	219 种胃肠炎相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L4000	经典已知活性库		14439 compounds
	14439 个已知活性化合物的集合，可用于高通量筛选、高内涵筛选、细胞诱导和靶点确认；
L5500	毒性化合物库		262 compounds
	262 个细胞毒性化合物的特有集合，可用于高通量、高内涵筛选。
L2910	抗氧化化合物库		1314 compounds
	氧化应激（Oxidative Stress，OS）是指体内氧化与抗氧化作用失衡的一种状态。氧化应激导致活性氧（ROS）大量积累，氧化程度超出抗氧化物的清除能力，从而引起氧化损伤，氧化应激损伤是许多疾病发生的基础，不同程度的氧化应激造成的细胞效应与心脑血管疾病、神经退行性病变、炎症和肿瘤密切相关。抗氧化剂是一类能够对抗氧化应激，降低氧化损伤的一类化合物。 TargetMol 抗氧化化合物库是1314 种对氧化应激具有抑制作用的小分子特有集合，是研究氧化应激的有用工具，可以用于高通量筛选和高内涵筛选。
L5800	药物代谢杂质库		197 compounds
	197 种药物异构体/代谢产物的特有集合，可用于高通量、高内涵筛选；
L2600	神经信号分子库		2540 compounds
	2540 种CNS 相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L6610	抗感染天然产物库		1060 compounds
	1060 个抗感染相关的天然产物集合，是药物开发、药理研究的有效工具；
L9411	半胱氨酸共价化合物库		70 compounds
	半胱氨酸共价库包含 70 个化合物。
L3700	JAK-STAT 化合物库		252 compounds
	252 个 JAK/STAT 靶点相关的小分子化合物的独特集合，用于高通量、高内涵筛选；
L6010	天然产物库		3840 compounds
	3840 种天然产物的独特集合，可用于高通量筛选和高内涵筛选；
L4100	TGF-β/Smad靶点化合物库		184 compounds
	184 个 TGF-β/Smad 靶点相关的小分子化合物的特有集合，用于高通量、高内涵筛选；
L3980	DNA损伤/修复库Plus		667 compounds
	667 种 DNA 损伤/修复靶向、结构新颖的化合物；
L3500	组蛋白修饰化合物库		469 compounds
	469 个组蛋白修饰相关的小分子化合物的特有集合，用于高通量、高内涵筛选；
L2200	酪氨酸激酶分子库		1016 compounds
	1016 种酪氨酸激酶抑制剂的独特集合，可用于高通量筛选和高内涵筛选；
L3100	造血毒性小分子库		101 compounds
	101 种生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L5400	抗心血管疾病化合物库		1408 compounds
	1408 种心血管疾病相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L2300	离子通道库		931 compounds
	931 种与离子通道相关的生物活性小分子化合物的特有集合，用于离子通道相关的疾病和药物研究，可用于高通量筛选和高内涵筛选；
L2160	抗癌活性化合物库		3188 compounds
	3188 种具有抗肿瘤活性的化合物的特有集合，用于高通量、高内涵筛选；
LF1000	多样性核心预制库		50000 compounds
	For your convenience, there are Diversity Sets of 5,000, 10,000, 15,000, and 20,000 compounds with no structure overlap.
L1600	激酶抑制剂库		2720 compounds
	2720 种激酶抑制剂/调节剂的独特集合，用于特定靶向激酶，可用于高通量筛选和高内涵筛选；
L2150	抗癌药物库		3080 compounds
	3080 个具有抗癌活性小分子的独特集合，生物活性已经临床前实验证实，可用于高通量、高内涵筛选；
L3600	细胞因子抑制剂库		604 compounds
	604 个与细胞因子紧密相关的化合物集合，是高通量、高内涵筛选的良好载体；
L2100	抗癌化合物库		7234 compounds
	7234 种肿瘤相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L3800	NF-κB 通路分子库		729 compounds
	729 个 NF-κB 信号通路相关的小分子化合物的特有集合，用于高通量、高内涵筛选；
L2100	抗癌化合物库		7234 compounds
	7234 种肿瘤相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L9200	药物功能重定位化合物库		4630 compounds
	4630 种全球上市药物和临床药物的独特集合，可用于高通量筛选和高内涵筛选，是老药新用、新的药物靶点筛选和细胞诱导的有效工具。
L8300	染色质修饰分子库		250 compounds
	250 种染色质化学修饰相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L2610	神经递质受体化合物库		1513 compounds
	1513 种与神经递质受体相关的化合物，用于高通量、高内涵筛选；
L9230	ReFRAME 相关化合物库		3210 compounds
	3210 化合物的独特集合，可用于高通量筛选和高内涵筛选
L4400	抗生素库		692 compounds
	692 个具有抗菌活性化合物的独特集合，是医药研究的优良工具库和药物筛选的有效载体；
L1510	核受体化合物库		531 compounds
	531 个核受体作用化合物的独特集合，可用于高通量筛选和高内涵筛选；
L8200	抗衰老化合物库		3279 compounds
	3279 个抗衰老化合物的独特集合，可用于高通量筛选和高内涵筛选；
L5900	血脑屏障通透化合物库		509 compounds
	509 个 CNS-Penetrant 生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L8800	药物片段库		1119 compounds
	1119 种药物片段分子，是FBDD 方法新药筛选的有力工具；
L4300	Wnt/Hedgehog/Notch 通路化合物库		237 compounds
	237 个Wnt & Hedgehog & Notch 靶点相关的生物活性小分子化合物的特有集合，用于相关通路的研究及药物的筛选，可用于高通量、高内涵筛选。
L7820	高溶解性微型片段化合物库		1081 compounds
	高溶解性微型片段化合物库由 1081 个低分子量片段组成。
L7860	Mini片段亲电杂环化合物库		369 compounds
	高溶解度共价杂环片段库中的 369 个化合物
L1300	PI3K/Akt/mTOR 化合物库		420 compounds
	420 种与PI3K/Akt/mTOR 相关的生物活性小分子化合物的特有集合，用于PI3K/Akt/mTOR 相关研究以及高通量、高内涵筛选；
L8400	血液病分子库		514 compounds
	514 种造血系统疾病相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L1000	上市药物库		2808 compounds
	2808 个上市药物化合物集合，可用于高通量筛选和高内涵筛选；
L1900	抗糖尿病库		683 compounds
	683 种生物活性小分子化合物；
L6700	抗癌天然产物库		1772 compounds
	1772 种已知活性天然产物的独特集合，是肿瘤药物开发、抗癌先导化合物筛选等领域的有力工具，可用于HTS 和HCS。
L2130	抗癌细胞代谢库		1268 compounds
	1268 种癌细胞代谢相关的生物活性小分子化合物的特有集合，用于肿瘤相关的研究以及抗肿瘤药物的筛选，用于高通量、高内涵筛选；
L6130	萜类天然产物库		622 compounds
	622 种萜类天然产物的独特集合，可用于高通量筛选和高内涵筛选；
L1800	抗感染化合物库		2938 compounds
	2938 种具有抗感染活性的化合物的特有集合，包括抗细菌、抗真菌、抗巨细胞病毒、抗HIV、抗SARS、抗流感等活性；
L4510	抗寄生虫库		419 compounds
	419 种具有抗寄生虫活性的小分子化合物；
L4600	植物来源化合物库		3048 compounds
	3048 个植物来源天然产物的独特集合，来自277类植物的精心之选；
L1010	FDA上市及药典收录分子库		3158 compounds
	3158 个上市及药典分子集合，可用于高通量筛选和高内涵筛选；
L6300	药食同源库		1290 compounds
	1290 个药食同源化合物的独特集合，可用于高通量筛选和高内涵筛选；
L6230	苗药化合物库		534 compounds
	534种苗族特色药材的天然产物分子，可用于高通量和高内涵筛选
L9850	口服活性化合物库		2427 compounds
	2427 种口服活性化合物独特集合，可用于高通量筛选和高内涵筛选
L6220	蒙药化合物库		950 compounds
	950 种蒙药来源的天然产物分子集合，可以用于高通量和高内涵筛选；
L1700	抗病毒库		1040 compounds
	1040 种具有抗病毒活性的化合物的特有集合，是筛选新型抗病毒药的有效工具；可用于高通量筛选和高内涵筛选；
L2501	人内源代谢化合物库 Plus		1283 compounds
	1283种内源性生物活性化合物的独特集合，用于高通量、高内涵筛选。
L6020	天然产物单体化合物库		16627 compounds
	16627 种精选天然产物集合，结构多样，遍布多种动植物与微生物；
L9210	儿童药物库		972 compounds
	972 种儿童药物的独特集合，可用于高通量筛选和高内涵筛选
L2140	癌细胞分化化合物库		406 compounds
	406 个诱导肿瘤细胞分化化合物的独特集合，可用于高通量筛选和高内涵筛选；
L2500	人内源代谢化合物库		499 compounds
	499 种内源性生物活性化合物的独特集合，用于高通量、高内涵筛选；
L7200	钙通道分子库		140 compounds
	140 种钙通道相关化合物的独特集合，可用于高通量筛选和高内涵筛选；
L7400	钠通道分子库		118 compounds
	118 种钠通道相关化合物的独特集合，可用于高通量筛选和高内涵筛选；
L7900	成骨分子库		317 compounds
	317 种成骨相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L1100	蛋白酶抑制剂库		343 compounds
	343 种已知的小分子蛋白酶抑制剂的特有集合，可用于高通量筛选和高内涵筛选；
L7700	神经再生化合物库		524 compounds
	524 种神经再生相关化合物的独特集合，可用于高通量筛选和高内涵筛选；
L6500	微生物天然产物库		550 compounds
	550 种微生物来源的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选；
L4020	NO PAINS 化合物库		9384 compounds
	TargetMol NO PAINS 化合物库包含 9384 个剔除了PAINS 的小分子活性化合物，可用于新药研发，信号通路研究，老药新用等研究。
L1400	MAPK 抑制剂库		365 compounds
	365 种与MAPK 信号通路相关的生物活性小分子化合物的特有集合，可用于高通量筛选和高内涵筛选；
L3200	自噬库		1248 compounds
	1248 种细胞自噬相关的生物活性小分子化合物的特有集合，用于自噬相关的研究，用于高通量、高内涵筛选；
L1610	FDA 上市激酶抑制剂库		263 compounds
	263种靶向激酶的上市药物集合，用于特定靶向激酶，可用于高通量筛选和高内涵筛选；
L1500	GPCR靶点分子库		1940 compounds
	1940 种与 G 蛋白及其耦联受体相关的生物活性小分子化合物，所有小分子都具有良好的生物和药理活性，部分是 FDA 批准的上市药物；
L6620	抗寄生虫天然产物库		253 compounds
	253 个抗寄生虫相关的天然产物集合，是药物开发、药理研究的有效工具；
L6210	藏药化合物库		747 compounds
	747 种藏药来源的天然产物分子集合，可以用于高通量和高内涵筛选；
L4800	血管生成库		1353 compounds
	1353 个高潜力的抑制或促进血管生成的小分子集合，可用于药物靶点开发、血管生成机理研究的高通量筛选，高内涵筛选；
L2110	抗癌上市药物库		1779 compounds
	1779 个具有抗癌活性小分子的独特集合，所有化合物都经过了严格的临床前研究和临床试验，由FDA、EMA 或NMPA 批准上市，可用于高通量、高内涵筛选。
L2195	抗前列腺癌化合物库		2070 compounds
	2070 种与前列腺癌相关的化合物，可以用于高通量和高内涵筛选
L2900	氧化还原化合物库		1264 compounds
	1264 个活性化合物，已经验证具有一定的抗氧化活性，包括 ROS 清除剂、iNOS、eNOS、及抗氧化的天然产物，是研究疾病机理以及药物研究的优良载体
L2180	抗肿瘤库Plus		1468 compounds
	1468 种抗肿瘤相关、结构新颖的化合物；
L7500	凝血与抗凝化合物库		144 compounds
	144 个化合物的独特集合，可用于高通量筛选和高内涵筛选；
L7600	趋化因子抑制剂库		59 compounds
	59 种趋化因子或其受体抑制剂的独特集合，可用于高通量筛选和高内涵筛选；
L4010	已知活性化合物库		22555 compounds
	22555 个已知活性化合物的集合，可用于高通量筛选、高内涵筛选、细胞诱导和靶点确认；
L3300	组胺&褪黑色素化合物库		153 compounds
	153 种生物活性小分子化合物，用于高通量、高内涵筛选；
L6400	海洋天然产物库		144 compounds
	144 种海洋来源的单体化合物，是药物开发、药理研究等领域的有力工具；
L2521	糖酵解化合物库		555 compounds
	555 种糖酵解相关的活性化合物，可用于高通量和高内涵筛选
L6820	烟草单体化合物库		747 compounds
	747种烟草单体化合物的独特集合，可用于高通量筛选和高内涵筛选
L4700	免疫/炎症分子化合物库		4720 compounds
	4720 种具有抗炎症活性的化合物的特有集合，可用于高通量筛选和高内涵筛选；
L2510	脂代谢化合物库		492 compounds
	492 个脂代谢相关的化合物集合，可用于高通量和高内涵筛选；
L5100	含氟化合物库		574 compounds
	574 个含氟化合物的独特集合，可用于高通量筛选和高内涵筛选；
L9700	内质网应激化合物库		193 compounds
	193 个内质网应激相关的化合物集合，可用于高通量和高内涵筛选；
L5700	精选片段库		246 compounds
	246 个片段小分子的独特集合，可用于基于片段的筛选和药物发现（FBDD）；
L2570	人代谢物化合物库		4454 compounds
	4454 种人代谢物的独特集合，用于高通量、高内涵筛选；
L2152	靶向治疗药物库		119 compounds
	119 个肿瘤靶向治疗药物，可以用于高通量和高内涵筛选；
L2151	化疗药物库		48 compounds
	48 个肿瘤化疗药物，可以用于高通量和高内涵筛选；
L6160	Ro5类药天然产物库		2703 compounds
	2703 种符合 RO5原则的天然产物单体集合，可以用于高通量和高内涵筛选；
L7300	钾通道分子库		152 compounds
	152 种钾通道相关化合物的独特集合，可用于高通量筛选和高内涵筛选；
L9400	PPI抑制剂库		485 compounds
	485 种已知活性的 PPI 相关的抑制剂，可用于高通量、高内涵筛选；
L6800	中国药典收录天然产物库		2051 compounds
	2051 种中国药典收录的天然产物，是药物开发、药理研究等领域的有力工具；
L4710	非甾体类抗炎化合物库		530 compounds
	530 种非甾体类的抗炎相关化合物，可用于高通量和高内涵筛选；
L9610	环肽库		80 compounds
	80 种环肽分子，可用于高通量和高内涵筛选；
L2194	抗结直肠癌化合物库		1545 compounds
	1545 种与结直肠癌相关的化合物，可以用于高通量和高内涵筛选；
L6200	瑶药化合物库		221 compounds
	221 种瑶药来源的天然产物分子集合，可以用于高通量和高内涵筛选；
L2560	代谢化合物库		2320 compounds
	2320 种代谢途径相关的化合物，可用于高通量和高内涵筛选。
L8720	细胞焦亡化合物库		1066 compounds
	1066 种细胞焦亡相关的化合物，可以用于细胞焦亡相关研究。
L6150	天然产物共价化合物库		583 compounds
	提供产品的生物学信息和药物学信息，为筛选提供理论方向和研究基础；
L7110	抗高血压化合物库		678 compounds
	678 种高血压相关的小分子，用于高通量和高内涵筛选；
L8600	泛素化化合物库		210 compounds
	210 种泛素化相关的小分子，用于高通量和高内涵筛选；
L8110	细胞重编程化合物库		1813 compounds
	1813 种重编程信号通路相关的生物活性小分子化合物的特有集合，可用于高通量、高内涵筛选
L3510	甲基化化合物库		128 compounds
	128 种甲基化相关的化合物，可以用于高通量和高内涵筛选；
L9860	抗抑郁症化合物库		1163 compounds
	1163 种与抑郁症相关的化合物，可以用于高通量和高内涵筛选
L6110	生物碱类天然产物库		500 compounds
	500 种生物碱类天然产物的独特集合，可用于高通量筛选和高内涵筛选；
L9000	细胞凋亡化合物库		1760 compounds
	1760 种与凋亡相关的生物活性小分子化合物的特有集合，多用于研究肿瘤发生发展机制和抗癌药物筛选等。可用于高通量筛选和高内涵筛选；
L2550	谷氨酰胺代谢化合物库		565 compounds
	565 种谷氨酰胺代谢相关的分子，可以用于高通量和高内涵筛选；
L5510	肝脏毒性化合物库		1001 compounds
	1001 个肝脏毒性化合物的特有集合，可用于高通量、高内涵筛选，是毒理学研究的良好工具；
L6120	黄酮类天然产物库		514 compounds
	514 种黄酮类天然产物的独特集合，可用于高通量筛选和高内涵筛选；
L9420	外泌体相关化合物库		76 compounds
	76 种外泌体相关的化合物，可以用于高通量和高内涵筛选；
L7100	抗肥胖化合物库		2247 compounds
	2247 个抗肥胖化合物的独特集合，可用于高通量筛选和高内涵筛选；
DO2200	共价抑制剂库CD		12000 compounds
	数量多：超过12000种共价结合化合物，并且数量在持续增加；
L2170	肿瘤免疫治疗小分子化合物库		449 compounds
	449 种靶向肿瘤免疫治疗靶点的小分子，可用于高通量和高内涵筛选，是研究肿瘤免疫治疗的有力工具；
L6720	抗COVID-19中药单体库		1147 compounds
	根据抗新冠肺炎疫情过程中应用于临床治疗的中药方剂，收集了1147 种相关中药来源的单体化合物，可用于高通量和高内涵筛选，是抗新冠病毒药物研发的良好工具；
L9300	大环化合物库		210 compounds
	210 种活性已知的大环化合物，用于高通量、高内涵筛选；

化合物库

表型筛选靶点鉴定库

Cat.No: L9500

Compounds: 1796

Mini真菌代谢天然产物筛选库

Cat.No: L6001

Compounds: Inquiry

半胱氨酸靶向共价抑制剂库

Cat.No: LF9000

Compounds: 3400

Cat.No: L5600

Compounds: 5000

Golden骨架库

Cat.No: L5610

Compounds: 10000

稀有天然产物库

Cat.No: L6900

Compounds: 693

Cat.No: L4500

Compounds: 252

天然多酚类化合物库

Cat.No: L6100

Compounds: 635

肾上腺素能受体化合物库

Cat.No: L2700

Compounds: 193

临床前化合物库

Cat.No: L3410

Compounds: 701

DNA 损伤和修复分子库

Cat.No: L3900

Compounds: 910

Cat.No: L2000

Compounds: 8328

磷酸酶抑制剂化合物库

Cat.No: L9100

Compounds: 79

内分泌激素分子库

Cat.No: L2400

Compounds: 784

FDA 上市药物库

Cat.No: L4200

Compounds: 1729

抗代谢疾病化合物库

Cat.No: L5200

Compounds: 1544

表观遗传库

Cat.No: L1200

Compounds: 953

干细胞分化化合物库

Cat.No: L8000

Compounds: 1197

农药化合物库

Cat.No: L9240

Compounds: 270

抗癌临床化合物库

Cat.No: L2120

Compounds: 2545

活性脂质化合物库

Cat.No: L7000

Compounds: 385

临床期小分子药物库

Cat.No: L3400

Compounds: 3404

天然产物衍生物虚筛化合物库

Cat.No: L6030

Compounds: 163000

5-羟色胺分子库

Cat.No: L2800

Compounds: 268

抗COVID-19化合物库

Cat.No: L1710

Compounds: 1133

细胞周期化合物库

Cat.No: L8100

Compounds: 677

胃肠炎天然产物库

Cat.No: L6600

Compounds: 219

经典已知活性库

Cat.No: L4000

Compounds: 14439

毒性化合物库

Cat.No: L5500

Compounds: 262

抗氧化化合物库

Cat.No: L2910

Compounds: 1314

药物代谢杂质库

Cat.No: L5800

Compounds: 197

神经信号分子库

Cat.No: L2600

Compounds: 2540

抗感染天然产物库

Cat.No: L6610

Compounds: 1060

半胱氨酸共价化合物库

Cat.No: L9411

Compounds: 70

JAK-STAT 化合物库

Cat.No: L3700

Compounds: 252

天然产物库

Cat.No: L6010

Compounds: 3840

TGF-β/Smad靶点化合物库

Cat.No: L4100

Compounds: 184

DNA损伤/修复库Plus

Cat.No: L3980

Compounds: 667

组蛋白修饰化合物库

Cat.No: L3500

Compounds: 469

酪氨酸激酶分子库

Cat.No: L2200

Compounds: 1016

造血毒性小分子库

Cat.No: L3100

Compounds: 101

抗心血管疾病化合物库

Cat.No: L5400

Compounds: 1408

离子通道库

Cat.No: L2300

Compounds: 931

抗癌活性化合物库

Cat.No: L2160

Compounds: 3188

多样性核心预制库

Cat.No: LF1000

Compounds: 50000

激酶抑制剂库

Cat.No: L1600

Compounds: 2720

抗癌药物库

Cat.No: L2150

Compounds: 3080

细胞因子抑制剂库

Cat.No: L3600

Compounds: 604

抗癌化合物库

Cat.No: L2100

Compounds: 7234

NF-κB 通路分子库

Cat.No: L3800

Compounds: 729

抗癌化合物库

Cat.No: L2100

Compounds: 7234

药物功能重定位化合物库

Cat.No: L9200

Compounds: 4630

染色质修饰分子库

Cat.No: L8300

Compounds: 250

神经递质受体化合物库

Cat.No: L2610

Compounds: 1513

ReFRAME 相关化合物库

Cat.No: L9230

Compounds: 3210

Cat.No: L4400

Compounds: 692

核受体化合物库

Cat.No: L1510

Compounds: 531

抗衰老化合物库

Cat.No: L8200

Compounds: 3279

血脑屏障通透化合物库

Cat.No: L5900

Compounds: 509

药物片段库

Cat.No: L8800

Compounds: 1119

Wnt/Hedgehog/Notch 通路化合物库

Cat.No: L4300

Compounds: 237

高溶解性微型片段化合物库

Cat.No: L7820

Compounds: 1081

Mini片段亲电杂环化合物库

Cat.No: L7860

Compounds: 369

PI3K/Akt/mTOR 化合物库

Cat.No: L1300

Compounds: 420

血液病分子库

Cat.No: L8400

Compounds: 514

上市药物库

Cat.No: L1000

Compounds: 2808

抗糖尿病库

Cat.No: L1900

Compounds: 683

抗癌天然产物库

Cat.No: L6700

Compounds: 1772

抗癌细胞代谢库

Cat.No: L2130

Compounds: 1268

萜类天然产物库

Cat.No: L6130

Compounds: 622

抗感染化合物库

Cat.No: L1800

Compounds: 2938

抗寄生虫库

Cat.No: L4510

Compounds: 419

植物来源化合物库

Cat.No: L4600

Compounds: 3048

FDA上市及药典收录分子库

Cat.No: L1010

Compounds: 3158

药食同源库

Cat.No: L6300

Compounds: 1290

苗药化合物库

Cat.No: L6230

Compounds: 534

口服活性化合物库

Cat.No: L9850

Compounds: 2427

蒙药化合物库

Cat.No: L6220

Compounds: 950

Cat.No: L1700

Compounds: 1040

人内源代谢化合物库 Plus

Cat.No: L2501

Compounds: 1283

天然产物单体化合物库

Cat.No: L6020

Compounds: 16627

儿童药物库

Cat.No: L9210

Compounds: 972

癌细胞分化化合物库

Cat.No: L2140

Compounds: 406

人内源代谢化合物库

Cat.No: L2500

Compounds: 499

钙通道分子库

Cat.No: L7200

Compounds: 140

钠通道分子库

Cat.No: L7400

Compounds: 118

成骨分子库

Cat.No: L7900

Compounds: 317

蛋白酶抑制剂库

Cat.No: L1100

Compounds: 343

神经再生化合物库

Cat.No: L7700

Compounds: 524

微生物天然产物库

Cat.No: L6500

Compounds: 550

NO PAINS 化合物库

Cat.No: L4020

Compounds: 9384

MAPK 抑制剂库

Cat.No: L1400

Compounds: 365

Cat.No: L3200

Compounds: 1248

FDA 上市激酶抑制剂库

Cat.No: L1610

Compounds: 263

GPCR靶点分子库

Cat.No: L1500

Compounds: 1940

抗寄生虫天然产物库

Cat.No: L6620

Compounds: 253

藏药化合物库

Cat.No: L6210

Compounds: 747

血管生成库

Cat.No: L4800

Compounds: 1353

抗癌上市药物库

Cat.No: L2110

Compounds: 1779

抗前列腺癌化合物库

Cat.No: L2195

Compounds: 2070

氧化还原化合物库

Cat.No: L2900

Compounds: 1264

抗肿瘤库Plus

Cat.No: L2180

Compounds: 1468

凝血与抗凝化合物库

Cat.No: L7500

Compounds: 144

趋化因子抑制剂库

Cat.No: L7600

Compounds: 59

已知活性化合物库

Cat.No: L4010

Compounds: 22555

组胺&褪黑色素化合物库

Cat.No: L3300

Compounds: 153

海洋天然产物库

Cat.No: L6400

Compounds: 144

糖酵解化合物库

Cat.No: L2521

Compounds: 555

烟草单体化合物库

Cat.No: L6820

Compounds: 747

免疫/炎症分子化合物库

Cat.No: L4700

Compounds: 4720

脂代谢化合物库

Cat.No: L2510

Compounds: 492

含氟化合物库

Cat.No: L5100

Compounds: 574

内质网应激化合物库

Cat.No: L9700

Compounds: 193

精选片段库

Cat.No: L5700

Compounds: 246

人代谢物化合物库

Cat.No: L2570

Compounds: 4454

靶向治疗药物库

Cat.No: L2152

Compounds: 119

化疗药物库

Cat.No: L2151

Compounds: 48

Ro5类药天然产物库

Cat.No: L6160

Compounds: 2703

钾通道分子库

Cat.No: L7300

Compounds: 152

PPI抑制剂库

Cat.No: L9400

Compounds: 485

中国药典收录天然产物库

Cat.No: L6800

Compounds: 2051

非甾体类抗炎化合物库

Cat.No: L4710

Compounds: 530

Cat.No: L9610

Compounds: 80

抗结直肠癌化合物库

Cat.No: L2194

Compounds: 1545

瑶药化合物库

Cat.No: L6200

Compounds: 221

代谢化合物库

Cat.No: L2560

Compounds: 2320

细胞焦亡化合物库

Cat.No: L8720

Compounds: 1066

天然产物共价化合物库

Cat.No: L6150

Compounds: 583

抗高血压化合物库

Cat.No: L7110

Compounds: 678

泛素化化合物库

Cat.No: L8600

Compounds: 210

细胞重编程化合物库

Cat.No: L8110

Compounds: 1813

甲基化化合物库

Cat.No: L3510

Compounds: 128

抗抑郁症化合物库

Cat.No: L9860

Compounds: 1163

生物碱类天然产物库

Cat.No: L6110

Compounds: 500

细胞凋亡化合物库

Cat.No: L9000

Compounds: 1760

谷氨酰胺代谢化合物库

Cat.No: L2550

Compounds: 565

肝脏毒性化合物库

Cat.No: L5510

Compounds: 1001

黄酮类天然产物库

Cat.No: L6120

Compounds: 514

外泌体相关化合物库

Cat.No: L9420

Compounds: 76

抗肥胖化合物库

Cat.No: L7100

Compounds: 2247

共价抑制剂库CD

Cat.No: DO2200

Compounds: 12000

肿瘤免疫治疗小分子化合物库

Cat.No: L2170

Compounds: 449

抗COVID-19中药单体库

Cat.No: L6720

Compounds: 1147

大环化合物库

Cat.No: L9300

Compounds: 210

Cat. No.	Product Name	Target	Signaling Pathways
T36421	Immuno-Oncology Screening Library	Others	Others
	The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list ...
T11344	G150	DNA; cGAS	DNA Damage/DNA Repair; Immunology/Inflammation
	G150 是高选择性h-cGAS 抑制剂，IC50值为 10.2 nM，用于抑制 dsDNA 引发的干扰素表达。
T21980	PD 198306	MEK	MAPK
	PD 198306 是一种具有抗痛觉过敏作用的 MAPK/ERK 激酶 (MEK) 选择性抑制剂。 PD 198306 可降低链脲佐菌素诱导的活性 ERK1 水平升高。
T13396	Zinc Protoporphyrin Zinc Protoporphyrin-9,锌原卟啉,ZnPP,Zn(II)-protoporphyrin IX	Apoptosis; Reactive Oxygen Species; Endogenous Metabolite	Apoptosis; Immunology/Inflammation; Metabolism; NF-κB
	Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) 是一种具有口服活性的，竞争性血红素加氧酶-1 抑制剂，显著减弱间苯三酚对 H2O2 的保护作用，具有抗癌活性。它用于评估人群铁状态与血红蛋白浓度的组合，也可用作个体孕妇和儿童缺铁的筛查标志物。
T67752	Compound V007-6018	Others	Others
	Compound V007-6018是一种类药化合物，用于药物筛选。
T4531	GSK2200150A	Antibacterial	Microbiology/Virology
	GSK2200150A 是一种通过高通量筛选活动确定的抗结核剂，对 H37Rv 的 MIC 是 0.38 μM。
T9212	IMB-301	Others; HIV Protease	Microbiology/Virology; Others; Proteases/Proteasome
	IMB-301是根据 hA3G 模型通过虚拟筛选的一种小分子抑制剂。
T14905	CCT251236	HSP	Cytoskeletal Signaling; Metabolism
	CCT251236 是基于细胞的表型高通量筛选（HTS）开发的化学探针，可用于筛选筛选来检测 HSF1 应激途径的抑制剂。CCT251236具有抗骨髓瘤活性，抑制 HSF1。
T3572	NSC 15364 1,3-Bis(4-aminophenyl)urea,NSC15364	Apoptosis; Others; VDAC	Apoptosis; Membrane transporter/Ion channel; Others
	NSC 15364 (1,3-Bis(4-aminophenyl)urea) 是一种 VDAC1寡聚化和细胞凋亡抑制剂。
T24859	TC-AQP1-1	Aquaporin	Membrane transporter/Ion channel
	TC-AQP1-1 是一种通过虚拟筛选鉴定的水通道蛋白 1 通道的阻断剂，并在低微摩尔浓度下抑制非洲爪蟾卵母细胞肿胀试验中通过 hAQP1 的水通量。
TP1204	iRGD peptide c(CRGDKGPDC)	Integrin	Cytoskeletal Signaling
	iRGD peptide (c(CRGDKGPDC)) 是由 9 个氨基酸组成的环肽，具有靶向肿瘤和肿瘤渗透的作用。
T4062	CAY10602	Sirtuin	Chromatin/Epigenetic; DNA Damage/DNA Repair
	CAY10602 是一种SIRT1激活剂，可剂量依赖性地抑制 THP-1 细胞中脂多糖对 TNF-α 的 NF-κB 依赖性诱导。
T41256	SP-96	Aurora Kinase	Cell Cycle/Checkpoint; Chromatin/Epigenetic
	SP-96 是一种高效的特异性 Aurora B 抑制剂，IC50 为 0.316 nM。 SP-96 在 NCI60 筛选中显示特异性生长抑制，如 MDA-MD-468 (GI50=107 nM)。 SP-96 可用于三阴性乳腺癌研究。
T12258	NSC 601980 (analog)	Others	Others
	NSC 601980 analog is the analog of the NSC601980 which shows antitumor activity in the yeast screening experiment.
T25542	Isamfazone Isamfazona,Isamfazonum	Others	Others
	Isamfazone is utilized in the chemical and pharmacological studies on substituted pyridazones, the discovery of novel anti-inflammatory agents by aligning screening.
T39185	pp60 (v-SRC) Autophosphorylation Site, Phosphorylated pp60 (v-SRC) Autophosphorylation Site, Phosphorylated
	pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is a phosphorylated peptide derived from an EGFR substrate. It serves as a valuable tool for quantifying phosphorylated substrates in screening EGFR Kinase inhibitors.
TP1476	WKYMVM TFA
	WKYMVm is a selective FPR2 agonist with high affinity, which was identified through screening of a synthetic peptide library.
T9536	Compound 1056090(SC)
	Compound 1056090(SC) 是一种筛选化合物，在生命科学相关研究中具有广泛的应用。
T9546	Compound D300-0270
	Compound D300-0270 是一种筛选化合物，在生命科学相关研究中具有广泛的应用。
T9535	Compound Z2922993434(SC)
	Compound Z2922993434(SC) 是一种筛选化合物，在生命科学相关研究中具有广泛的应用。
T85319	(Z)-2-fluoro-1,3-bis(4-methoxyphenyl)prop-2-en-1-one SJD00639	Others	Others
	(Z)-2-fluoro-1,3-bis(4-methoxyphenyl)prop-2-en-1-one 是一种筛选化合物，可用于新药研发相关研究。
T73752	Glutarylcarnitine lithium	Others	Others
	Glutarylcarnitine lithium 丙二酸尿症和 I 型戊二酸尿症的重要诊断代谢物。
T74626	BBR-BODIPY
	BBR-BODIPY 是一种荧光探针 (fluorescent probe)，可以筛选其与靶细胞的相互作用。BBR-BODIPY 诱导细胞凋亡改变凋亡相关蛋白的表达。储存方式：避光。
T12259	NSC 601980	Others	Others
	NSC 601980 酵母筛选实验结果中显示了抗肿瘤活性, 能够在COLO 205 and HT29细胞株里很好的抑制细胞增殖，Log GI 50分别是-6.6和 -6.9。
T83800	6-Biotin-17-NAD+ sodium 6-Biotin-17-Nicotinamide adenine dinucleotide,β-Nicotinamide-N6-(2-(6-(6-[biotinyl]aminohexanoyl)aminohexanoyl)aminoethyl)adenine dinucleotide
	6-Biotin-17-NAD+ 是信号分子及酶辅因子NAD+的生物素化衍生物，已应用于高通量筛选(HTS)中，用于测定线粒体复合物I（又称NADH脱氢酶）的活性。
T14529L	Bentiromide acetate Bentiromide acetate(37106-97-1 Free base)	Others	Others
	Bentiromide acetate 是一种肽，用于外分泌胰腺功能不全的筛选试验和监测补充胰腺治疗的充分性。它被胰酶胰凝乳蛋白酶分解，生成对氨基苯甲酸(PABA)。
T69911	CU-6PMN	Others	Others
	CU-6PM is a new fluorescent RXR agonist. CU-6PMN was designed based on the fact that umbelliferone emits strong fluorescence in a hydrophilic environment, but the fluorescence intensity decreases in hydrophobic environments such as the interior of proteins. The developed assay CU-6PMN enabled screening of rexinoids to be performed easily within a few hours by monitoring changes of fluorescence intensity with widely available fluorescence microplate readers, without the need for processes such a...
T80151	α-Synuclein 4554W
	α-Synuclein4554W是一种α-Synuclein(aSyn)聚集抑制剂，对应毒性相关。它含GIVNGVKA序列，该序列通过细胞内文库筛选鉴定而来。α-Synuclein4554W能够减少与帕金森病相关的aSyn突变体的原纤维形成。
T36743	CDK7/9 tide
	CDK7/9 tide is peptide substrate for CDK7 or CDK9[1]. [1]. Robert T, et, al. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27; 8:147.
T35411	(+)-Biotin 4-Amidobenzoic Acid (sodium salt)	Others	Others
	(+)-Biotin 4-amidobenzoic acid is a substrate of biotinidase, which cleaves biotin amide to give biotin in vivo. Biotin is an essential coenzyme for certain carboxylases and is used to modify histones and regulate gene transcription. Biotinidase has key roles in intestinal absorption of biotin, the transport of biotin in plasma, and in the regulation of histone biotinylation. (+)-Biotin 4-amidobenzoic acid is hydrolyzed by biotinidase to release 4-aminobenzoic acid (PABA), which can be quantifie...
T79556	NDBM	Autophagy	Autophagy
	NDBM为一种结合Pim-1 kinase的肿瘤特异性探针，具备释放强荧光及细胞毒性，用于筛选及杀伤肿瘤细胞。该化合物特异性地靶向溶酶体并对pH值具有高度敏感性，适用于监测自噬(autophagy)过程及细胞内环境在外部刺激下的pH变化。
T78520	CYT296	Others	Others
	CYT296是一种靶向染色质去凝集的化合物，能增强定义因子(OSKM)介导诱导多能干细胞(iPSC)的生成，并通过诱导小鼠胚胎成纤维细胞(MEFs)染色质的开放状态来促进体细胞的重编程，适用于细胞替代治疗和药物筛选的研究领域。
T69117	Pinafide	Others	Others
	Pinafide is a rodenticide and anti-protozoal agent. Pinafide shows strong cytostatic activity against both HeLa and KB cells and is moderately toxic to both mice and rats. It has been proved active against experimental tumors and shown to be inhibitor of two DNA viruses. Pinafide blocks cell growth by inhibiting DNA and RNA synthesis. It has been shown to bind to double-helical DNA by intercalation. Pinafide inhibited the activity of M. tuberculosis NAD⁺-dependent DNA ligase A at concentrations ...
T82789	Caloxin 1B1
	Caloxin 1B1是一种对PMCA4亲和力高的生物活性肽。该化合物是经由筛选与PMCA4胞外结构域1的结合而发现，能够特异性地在胞外环境中抑制PMCA。鉴于Caloxin 1B1被筛选用于与PMCA的细胞外结构域相结合，它可以被直接应用于细胞和组织中，用以评估其对平滑肌和内皮细胞功能的影响。
T35706	25-Desacetyl Rifampicin	Others	Others
	25-Desacetyl rifampicin is a major active metabolite of the rifamycin antibiotic rifampicin .125-Desacetyl rifampicin is active againstM. smegmatis(MIC99= 2.66 μM). 1.Kigondu, E.M., Njoroge, M., Singh, K., et al.Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolitesMed. Chem. Commun.5502-506(2014)
T35905	Oasomycin B	Others	Others
	Oasomycin B is a bacterial metabolite that has been found inS. baldaciiand has antiprotozoal activity.1It is active againstT. vaginalis(MIC = 62.5 μg/ml). 1.Grabley, S., Kretzschmar, G., Mayer, M., et al.Secondary metabolites by chemical screening, 24. Oasomycins, new macrolactones of the desertomycin familyLiebigs Ann. Chem.5573-589(1993)
T38187	6-Aminophenanthridine	Others	Others
	6-Aminophenanthridine is an antiprion agent. It inhibits prion formation in yeast- and mammalian-based screening assays when used alone and, to a greater extent, when used in combination with the α2-adrenergic receptor agonist guanabenz . 6-Aminophenanthridine (300 μM) inhibits protein folding activity of the ribosome (PFAR) by directly competing with protein substrates for the active site and decreases the yield of refolded protein without affecting the refolding rate. It prevents progressive w...
T83131	AMC-GlcNAc
	AMC-GlcNAc (compound 1) 作为一款高效荧光探针，主要用于β-己糖胺酶活性的检测与表征。该探针能在连续监测中开启荧光，并且在宽广pH值范围内维持稳定的荧光信号（Ex=325 nm, Em=390 nm）。AMC-GlcNAc还支持高灵敏度与低背景信号的比率荧光检测，适用于筛选大肠杆菌细胞裂解物中重组分散素B的活性。
T37062	L-Leucine-7-amido-4-methylcoumarin hydrochloride
	L-Leu-AMC is a fluorogenic substrate for leucine aminopeptidase.1Upon enzymatic cleavage by leucine aminopeptidase, AMC is released and its fluorescence can be used to quantify leucine aminopeptidase activity. AMC displays excitation/emission maxima of 340-360/440-460 nm, respectively. 1.Izquierdo, M., Lin, D., O’Neill, S., et al.Development of a high-throughput screening assay to identify inhibitors of the major M17-leucyl aminopeptidase from Trypanosoma cruzi using rapidfire mass spectrometryS...
T83952	CoraFluor 1, amine reactive
	CoraFluor 1 (胺活性) 是一种基于铽的时间分辨福斯特共振能量转移(TR-FRET)供体，专为TR-FRET检测开发而设计，适用于目标结合和三元复合物检测等应用。该产品采用PFP酯，能与初级胺反应，适合标记生物分子如抗体、纳米体、蛋白质和肽段。CoraFluor 1 (胺活性) 具有极高的亮度，提供了在生物介质中的无与伦比的检测灵敏度和稳定性，超过其他市面上可获得的TR-FRET供体。它与常见的受体染料如FAM、TMR和Cyanine 5, SE兼容，能够无缝集成于高通量筛选应用中。
T37721	Dihydronovobiocin	Others	Others
	Dihydronovobiocin is a coumarin antibiotic and derivative of novobiocin .1It is active against the bacteriaS. aureus,S. haemolyticus,D. pneumoniae,S. typhosa,K. pneumoniae, andP. multocida(MICs = 0.6, 2, 0.6, 10, 10, and 3 μg/ml, respectively).2Dihydronovobiocin inhibits DNA gyrase subunit B with an IC50value of 64.5 nM.3 1.Berger, J., and Batcho, A.D.Coumarin - glycoside antibioticsJ. Chromatogr. Lib.15101-158(1978) 2.Hoeksema, H.Dihydronovobiocin and derivatives thereof3,175,9441-9(1965) 3.Gev...
T37614	LDN-0088050	Others	Others
	LDN 0088050 is selectivity adipocyte fatty acid binding protein (AFABP, FABP4) inhibitor with Ki values of 0.29 and 1.3 μM for FABP4 and FABP3, respectively. LDN 0088050 binds to FABP4 with a Kd of 2.05 μM[1]. Ki: 0.29 μM (FABP4), 1.3 μM (FABP3)[1]Kd: 2.05 μM (FABP4)[1] LDN 0088050 significantly inhibits LPS-induced expression of both TNFα and IL-6 in RAW264.7 cells[1]. [1]. Zhou Y, et al. The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biolo...
T37431	ENPP1 Inhibitor C ENPP1 Inhibitor C	Others	Others
	ENPP1 inhibitor C is an inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1; IC50 = 0.26 μM in a cell-free assay).1 It is selective for ENPP1 over ENPP2-7 at 10 μM. ENPP1 inhibitor C decreases ENPP1 activity in MDA-MB-231 human breast and C6 rat glioma cancer cells when used at a concentration of 10 μM. \|1. Kawaguchi, M., Han, X., Hisada, T., et al. Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging, and prognostic assessment of malignant brea...
T36695	TAS-103	Others	Others
	TAS-103 is a dual inhibitor of DNA topoisomerase I/II, used for cancer research. TAS-103 is a dual inhibitor of DNA topoisomerase I/II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells[1]. TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103[2]. TAS-103 inhibits the viability ...

化合物

Immuno-Oncology Screening Library

Cat.No: T36421

Target: Others

Cat.No: T11344

Target: DNA, cGAS

Cat.No: T21980

Target: MEK

Zinc Protoporphyrin

Cat.No: T13396

Synonym: Zinc Protoporphyrin-9,锌原卟啉,ZnPP,Zn(II)-protoporphyrin IX

Target: Apoptosis, Reactive Oxygen Species, Endogenous Metabolite

Compound V007-6018

Cat.No: T67752

Target: Others

Cat.No: T4531

Target: Antibacterial

Cat.No: T9212

Target: Others, HIV Protease

Cat.No: T14905

Target: HSP

Cat.No: T3572

Synonym: 1,3-Bis(4-aminophenyl)urea,NSC15364

Target: Apoptosis, Others, VDAC

Cat.No: T24859

Target: Aquaporin

Cat.No: TP1204

Synonym: c(CRGDKGPDC)

Target: Integrin

Cat.No: T4062

Target: Sirtuin

Cat.No: T41256

Target: Aurora Kinase

NSC 601980 (analog)

Cat.No: T12258

Target: Others

Cat.No: T25542

Synonym: Isamfazona,Isamfazonum

Target: Others

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

Cat.No: T39185

Synonym: pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

Cat.No: TP1476

Compound 1056090(SC)

Cat.No: T9536

Compound D300-0270

Cat.No: T9546

Compound Z2922993434(SC)

Cat.No: T9535

(Z)-2-fluoro-1,3-bis(4-methoxyphenyl)prop-2-en-1-one

Cat.No: T85319

Synonym: SJD00639

Target: Others

Glutarylcarnitine lithium

Cat.No: T73752

Target: Others

Cat.No: T74626

Cat.No: T12259

Target: Others

6-Biotin-17-NAD+ sodium

Cat.No: T83800

Synonym: 6-Biotin-17-Nicotinamide adenine dinucleotide,β-Nicotinamide-N6-(2-(6-(6-[biotinyl]aminohexanoyl)aminohexanoyl)aminoethyl)adenine dinucleotide

Bentiromide acetate

Cat.No: T14529L

Synonym: Bentiromide acetate(37106-97-1 Free base)

Target: Others

Cat.No: T69911

Target: Others

α-Synuclein 4554W

Cat.No: T80151

Cat.No: T36743

(+)-Biotin 4-Amidobenzoic Acid (sodium salt)

Cat.No: T35411

Target: Others

Cat.No: T79556

Target: Autophagy

Cat.No: T78520

Target: Others

Cat.No: T69117

Target: Others

Cat.No: T82789

25-Desacetyl Rifampicin

Cat.No: T35706

Target: Others

Cat.No: T35905

Target: Others

6-Aminophenanthridine

Cat.No: T38187

Target: Others

Cat.No: T83131

L-Leucine-7-amido-4-methylcoumarin hydrochloride

Cat.No: T37062

CoraFluor 1, amine reactive

Cat.No: T83952

Dihydronovobiocin

Cat.No: T37721

Target: Others

Cat.No: T37614

Target: Others

ENPP1 Inhibitor C

Cat.No: T37431

Synonym: ENPP1 Inhibitor C

Target: Others

Cat.No: T36695

Target: Others

Cat. No.	Product Name	Target	Signaling Pathways
T17143	Toyocamycin 丰加霉素,Vengicide	Apoptosis; Others; IRE1; Antibiotic; Antifungal	Apoptosis; Cell Cycle/Checkpoint; Microbiology/Virology; Others
	Toyocamycin (Vengicide) 是放线菌类产生的腺苷类似物，为 X 盒结合蛋白 1 (XBP1) 抑制剂，抑制 IRE1α 诱导的 ATP 依赖性 XBP1 mRNA 的断裂，IC50值为 80 nM。它还诱导凋亡。
T4925	Thiamine monophosphate chloride (dihydrate) Thiamine monophosphate chloride dihydrat,胺氯化亚磷酸酯,Aneurine monophosphate chloride	Others; Endogenous Metabolite	Metabolism; Others
	Thiamine monophosphate chloride dihydrate (Aneurine monophosphate chloride) 是内源性代谢产物的一种。
T4S0051	Coptisine sulfate	Indoleamine 2,3-Dioxygenase (IDO)	Metabolism
	Coptisine Sulfate 是一种从黄连中分离到的生物碱，是非竞争性的IDO 抑制剂，Ki=为 5.8 μM，IC50=6.3 μM。
T3313	D-Luciferin Firefly luciferin,D-萤光素,D-荧光素,D-(-)-Luciferin	Others	Others
	D-Luciferin (D-(-)-Luciferin) 是一种萤光素酶的底物，能够催化生物发光昆虫产生典型的黄绿光。
T19340	Glutarylcarnitine O-glutaroyl-L-carnitine	Endogenous Metabolite	Metabolism
	Glutarylcarnitine (O-glutaroyl-L-carnitine) 是大多数串联质谱新生儿筛查计划中监测的丙二酸尿症和谷草酸尿症 I 型的诊断代谢物。
T3888	Scopolin Murrayin,东莨菪甙,Scopoloside,东莨菪苷	Sirtuin	Chromatin/Epigenetic; DNA Damage/DNA Repair
	Scopolin (Scopoloside) 是从拟南芥根中分离出来的香豆素，可通过激活SIRT1介导的信号级联反应减轻了肝脂肪变性。
TN1583	Dihydromorin	TRP/TRPV Channel	Membrane transporter/Ion channel
	trans-Dihydromorin is an effective hypopigmenting agent in normal skin cells, hypopigmenting agents effective in melanoma system may not be effective on normal melanocytes, indicating that a non-tumor melanocyte system is more suitable for the screening o
TN5243	Vitexilactone	NADPH-oxidase; HIV Protease; Antifection	Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome
	Vitexilactone is a HIV-1 reverse transcriptase inhibitor in virtual screening against Indonesian Herbal Database using AutoDock4 performed on HIV-1 reverse transcriptase. It has trypanocidal activity, the minimum lethal concentration against epimastigotes
TN5578	Abieta-8,11,13-triene-7,15,18-triol
	Abieta-8,11,13-triene-7alpha,15,18-triol,7alpha,8alpha,13beta,14beta-diepoxyabietan-18-oic acid, and 18-nor-abieta-8,11,13-triene-4alpha,7alpha,15-triol may have inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by the tum
T38038	(-)-Rasfonin	Others	Others
	(-)-Rasfonin is a fungal metabolite that has been found in T. terrophilus.1 It inhibits proliferation of mouse splenocytes induced by concanavalin A and LPS (IC50s = 0.7 and 0.5 μg/ml, respectively). References1. Fujimoto, H., Okamoto, Y., Sone, E., et al. Eleven new 2-pyrones from a fungi imperfecti, Trichurus terrophilus, found in a screening study guided by immunomodulatory activity. Chem. Pharm. Bull. (Tokyo) 53(8), 923-929 (2005).
T35761	Carviolin	Others	Others
	Carviolin is an anthraquinone fungal metabolite that has been found inZ. longicaudatawith immunosuppressive and antitrypanosomal activities.1,2It inhibits LPS- or concanavalin A-induced proliferation of mouse splenocytes (IC50s = 4 and 4.5 μg/ml, respectively).1Carviolin is active againstT. b. brucei(MIC = 41.66 μM).2 1.Fujimoto, H., Nakamura, E., Okuyama, E., et al.Six immunosuppressive features from an ascomycete, Zopfiella longicaudata, found in a screening study monitored by immunomodulatory...
T37690	Phenylpyropene A	Others	Others
	Phenylpyropene A is a fungal metabolite originally isolated from P. griseofulvum that has enzyme inhibitory and insecticidal activities.1,2,3 It inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT; IC50 = 0.8 μM).1 Phenylpyropene A inhibits diacylglycerol acyltransferase (DGAT) in rat liver microsomes (IC50 = 78.7 μM). It induces mortality in 100% of M. persicae when used at a concentration of 5 ppm.3 \|1. Kwon, O.E., Rho, M.C., Song, H.Y., et al. Phenylpyropene A and B, new inhibitors of ...

天然产物

Cat.No: T17143

Synonym: 丰加霉素,Vengicide

Target: Apoptosis, Others, IRE1, Antibiotic, Antifungal

Thiamine monophosphate chloride (dihydrate)

Cat.No: T4925

Synonym: Thiamine monophosphate chloride dihydrat,胺氯化亚磷酸酯,Aneurine monophosphate chloride

Target: Others, Endogenous Metabolite

Coptisine sulfate

Cat.No: T4S0051

Target: Indoleamine 2,3-Dioxygenase (IDO)

Cat.No: T3313

Synonym: Firefly luciferin,D-萤光素,D-荧光素,D-(-)-Luciferin

Target: Others

Glutarylcarnitine

Cat.No: T19340

Synonym: O-glutaroyl-L-carnitine

Target: Endogenous Metabolite

Cat.No: T3888

Synonym: Murrayin,东莨菪甙,Scopoloside,东莨菪苷

Target: Sirtuin

Cat.No: TN1583

Target: TRP/TRPV Channel

Cat.No: TN5243

Target: NADPH-oxidase, HIV Protease, Antifection

Abieta-8,11,13-triene-7,15,18-triol

Cat.No: TN5578

Cat.No: T38038

Target: Others

Cat.No: T35761

Target: Others

Phenylpyropene A

Cat.No: T37690

Target: Others

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPY-03962	AFM Protein, Human, Recombinant (His) afamin,ALBA,ALB2,ALF	Human	HEK293 Cells
	Afamin is an 87 kDa glycoprotein with five predicted N-glycosylation sites. Afamin's glycan abundance contributes to conformational and chemical inhomogeneity presenting great challenges for molecular structure determination. Afamin, a human plasma glycoprotein and putative transporter of hydrophobic molecules, has been shown to act as extracellular chaperone for poorly soluble, acylated Wnt proteins, forming a stable, soluble complex with functioning Wnt proteins. The 2.1-Å crystal structure of...
TMPK-01462	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS,K-RAS2B,K-Ra...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01450	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras 2,C-K-RAS,RASK2,K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01405	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-RAS2A,K-RAS2B,GTPa...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01460	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras,K-RAS2B,C-K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01428	HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi) CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RALD,KI-RAS,K-RAS2A,M...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01443	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,KRAS2,NS3...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01526	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) KRAS,NS3,GTPase Kras,RASK2,K-RAS2B,C-K-RAS,MHC,KRAS2,KI-RAS,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01490	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS2A,GTPase Kras,K-Ras 2,RALD,KRAS2,K-RAS4A,MHC,K-RAS4B,C...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01453	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated RASK2,CFC2,K-Ras 2,NS3,GTPase Kras,KRAS1,K-RAS4B,K-RAS2B,MHC...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01464	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-RAS2B,MHC,KRAS2,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01537	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS4A,NS,C-K-RAS,RALD,GTPase Kras,K-RAS2A,K-RAS4B,CFC2,RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01536	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase Kras,K-Ras 2,K-RAS2A,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01457	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-Ras 2,CFC2,RALD,MHC,KRAS,K-RAS4B,NS3,C-K-RAS,NS,KI-RAS,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01431	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi) RALD,C-K-RAS,MHC,K-RAS2A,GTPase Kras,KRAS,NS,RASK2,K-RAS4B,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01439	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled KRAS,GTPase Kras,K-RAS2A,K-RAS4A,NS,CFC2,RALD,MHC,C-K-RAS,NS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01440	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CFC2,K-Ras ...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01432	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-RAS2B,C-K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01435	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled KRAS2,NS3,RASK2,KI-RAS,RALD,K-RAS2B,K-RAS4B,GTPase Kras,C-K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01430	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-RAS2B,K-RAS4A,KRAS1...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01465	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS2A,CFC2,KRAS,GTPase Kras,K-RAS2B,K-Ras 2,KI-RAS,C-K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B,KI-RAS,K-Ras 2,RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01402	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated KRAS1,NS,CFC2,K-RAS4B,RASK2,K-Ras 2,KI-RAS,GTPase Kras,KRAS,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01528	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K-Ras 2,KI-RAS,K-RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01507	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi) K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,NS,MHC,NS3,K-RAS4A...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01404	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4B,K-RAS2B...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01434	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-RAS2A,K-RAS4A,KRAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01525	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,KRAS2,K-RAS4B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01403	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,RALD,NS3,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01461	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B,K-RAS2B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01427	HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CFC2,RASK2...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01463	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3,K-RAS2B,NS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01429	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-RAS2A,K-RAS2B,RALD,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01518	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RASK2,C-K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01527	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K-RAS2A,K-RAS4A,KRA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01408	HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase Kras,MHC,K-RAS2A,KI...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01433	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi) GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RAS4A,CFC2,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01458	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,KRAS1,RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451	HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,CFC2,K-RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01529	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4B,KRAS2,NS3...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

重组蛋白

AFM Protein, Human, Recombinant (His)

Cat.No: TMPY-03962

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01462

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01450

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01405

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01460

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01428

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

Cat.No: TMPK-01443

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01526

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01490

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01453

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01464

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01537

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01536

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01457

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01431

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01439

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01440

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01432

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01435

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01430

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01465

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01456

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01402

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01528

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01507

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01404

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01434

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01525

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01403

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01461

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01427

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01463

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01429

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01518

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01527

Species: Human

Expression System: HEK293 Cells

HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01408

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01433

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01458

Species: Human

Expression System: HEK293 Cells

HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01451

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01529

Species: Human

Expression System: HEK293 Cells

Cat. No.	Product Name	Target	Signaling Pathways
TMIJ-0052	Propionicacid-d5
	Propionicacid-d5 是 Propionicacid 的氘代化合物。Propionicacid 的 CAS 号为 79-09-4。Propionic acid 被广泛用作食品中的抗真菌剂。它以低水平天然存在于乳制品中，并与其他短链脂肪酸 (SCFA) 一起普遍存在于人类和其他哺乳动物的胃肠道中，作为微生物消化碳水化合物的最终产物。在动物体内有显着的生理活性。
TMIJ-0054	Propionic-2,2-d2 acid
	Propionic-2,2-d2 acid 是 Propionic acid 的氘代化合物。Propionic acid 的 CAS 号为 79-09-4。Propionic acid 被广泛用作食品中的抗真菌剂。它以低水平天然存在于乳制品中，并与其他短链脂肪酸 (SCFA) 一起普遍存在于人类和其他哺乳动物的胃肠道中，作为微生物消化碳水化合物的最终产物。在动物体内有显着的生理活性。

同位素标记化合物

Propionicacid-d5

Cat.No: TMIJ-0052

Propionic-2,2-d2 acid

Cat.No: TMIJ-0054

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼